255 completed, 83 terminated, 28 recruiting, 26 withdrawn. 172 Phase 1, 164 Phase 2, 50 Not applicable, 32 Phase 3, 6 Early Phase 1.
Follow Mycosis Fungoides: new trials by email Literature Review of Mycosis Fungoides trials Research Report on Mycosis Fungoides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides Duvelisib - Mycosis Fungoides, Cutaneous T-cell Lymphoma | Phase 1 | Not yet recruiting | SecuraBio | 30 | 2027-01-01 | 2026-07-20 |
| A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Medsyn Biopharma, LLC | 75 | 2026-11-01 | 2026-10-27 |
| Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia Golidocitinib - Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Washington University School of Medicine | 24 | 2026-09-30 | 2026-07-06 |
| A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma KK2223 - T-cell NHL (PTCL or CTCL) | Phase 1 | Recruiting | Kyowa Kirin, Inc. | 72 | 2026-09-02 | 2026-09-30 |
| Topical JAK-Inhibition of Early-Stage CTCL delgocitinib - Mycosis Fungoides, Cutaneous T-cell Lymphoma | Phase 2 | Not yet recruiting | Aarhus University Hospital | 15 | 2026-09-01 | 2026-08-26 |
| Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL) Brentuximab Vedotin (Bv), Lisaftoclax (APG-2575) - Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Not yet recruiting | Peking University First Hospital | 46 | 2026-07-31 | 2026-07-23 |
| A Study of VG712 in Patients With Mycosis Fungoides VG712, Mogamulizumab - Mycosis Fungoides | Phase 2 | Not yet recruiting | Virogen Biotechnology Inc. | 386 | 2026-07-30 | 2026-04-14 |
| Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma Benvitimod Cream, Placebo cream - Cutaneous T-Cell Lymphoma, Mycosis Fungoides (MF) | Phase 2 | Not yet recruiting | Peking University First Hospital | 35 | 2026-07-01 | 2026-06-22 |
| Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides A-dmDT390-bisFv(UCHT1), Vorinostat - Mycosis Fungoides | Phase 2 | Withdrawn | Virogen Biotechnology Inc. | 2026-05-01 | 2026-05-18 | |
| A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) DT-7012 - Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides | Early Phase 1 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2026-01-01 | 2025-10-09 |
| A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells - Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 60 | 2025-09-29 | 2026-10-16 |
| Long-term Assessment of Chlormethine Gel in Mycosis Fungoides Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Not yet recruiting | Fondazione Italiana Linfomi - ETS | 190 | 2025-09-01 | 2025-07-04 | |
| SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS) | Recruiting | Leiden University Medical Center | 840 | 2025-07-29 | 2025-08-19 | |
| Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance Poteligeo 20mg - Mycosis Fungoides, Sezary Syndrome | Recruiting | Kyowa Kirin Co., Ltd. | 15 | 2025-05-02 | 2025-09-22 | |
| A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL PTX-100 - CTCL | Phase 2 | Recruiting | Prescient Therapeutics, Ltd. | 115 | 2025-03-28 | 2026-09-09 |
| Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Recruiting | Fondazione Italiana Linfomi - ETS | 400 | 2025-02-27 | 2025-12-02 | |
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL Hypericin, Placebo - CTCL/ Mycosis Fungoides, CTCL | Phase 3 | Terminated | Soligenix | 70 | 2025-01-07 | 2026-07-13 |
| IL-35: A Key Immunosuppressive Driver in Mycosis Fungoides Modulated by Phototherapy Phototherapy (PUVA or NB-UVB) - Mycosis Fungoides | Not applicable | Completed | Kasr El Aini Hospital | 16 | 2025-01-01 | 2025-11-19 |
| JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas JAK1 Inhibitor - Lymphoma, T-Cell, NK-LGL Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 48 | 2024-12-25 | 2025-11-18 |
| A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab Non-Interventional Study - Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome | Recruiting | City of Hope Medical Center | 100 | 2024-12-06 | 2026-09-14 |
Showing 20 of 445. Sign in to see all of them.
Lymphoma, T-Cell, Cutaneous (370) · Sezary Syndrome (354) · Leukemia, Lymphocytic, Chronic, B-Cell (242) · Lymphoma, Follicular (241) · Lymphoma, Large B-Cell, Diffuse (240) · Lymphoma, B-Cell, Marginal Zone (235) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (235) · Lymphoma, Mantle-Cell (234) · Lymphoma, Non-Hodgkin (234) · Burkitt Lymphoma (227) · Hodgkin Disease (220) · Lymphoma, Large-Cell, Immunoblastic (216) · Lymphoma, Large-Cell, Anaplastic (189) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (185)
Hemic and Lymphatic Diseases (445) · Neoplasms by Histologic Type (445) · Immunoproliferative Disorders (442) · Lymphatic Diseases (442) · Immune System Diseases (441) · Lymphoma, T-Cell (414) · Lymphoproliferative Disorders (413) · Neoplasms (402) · Hematologic Diseases (266) · Leukemia, Lymphoid (262) · Lymphoma (262) · Pathological Conditions, Signs and Symptoms (257) · Pathologic Processes (254) · Disease Attributes (253) · Lymphoma, B-Cell (249)
Peripheral Blood Stem Cell Transplantation (39) · fludarabine phosphate (37) · Cyclophosphamide (33) · Mycophenolic Acid (28) · Cyclosporine (24) · Whole-Body Irradiation (24) · Tacrolimus (22) · Radiotherapy (19) · Busulfan (18) · Methotrexate (18) · Antilymphocyte Serum (17) · Etoposide (14) · Filgrastim (14) · Flow Cytometry (14) · Bexarotene (11)
National Cancer Institute (NCI) (51) · Fred Hutchinson Cancer Center (32) · Mayo Clinic (18) · Northwestern University (18) · City of Hope Medical Center (17) · M.D. Anderson Cancer Center (16) · Memorial Sloan Kettering Cancer Center (13) · Case Comprehensive Cancer Center (12) · European Organisation for Research and Treatment of Cancer - EORTC (12) · National Institutes of Health Clinical Center (CC) (10) · Jonsson Comprehensive Cancer Center (8) · Vanderbilt-Ingram Cancer Center (8) · Roswell Park Cancer Institute (7) · Stanford University (7) · Wake Forest University Health Sciences (7)
United States (359) · Italy (29) · Germany (22) · France (20) · United Kingdom (18) · Switzerland (17) · Spain (16) · Canada (14) · Belgium (13) · Austria (12) · Australia (10) · Netherlands (7) · Poland (7) · Turkey (Türkiye) (5) · China (4)
Timothy M. Kuzel, MD (5) · Brenda Sandmaier (4) · David Maloney (4) · Madeleine Duvic, MD (4) · Roger Strair, MD, PhD (4) · Shivaani Kummar, MD (4) · Ajay Gopal (3) · Barbara Pro, MD (3) · David G. Savage, MD (3) · Diana M. Escolar, MD, FAAN (3) · Kyoo H. Lee, MD (3) · Larisa J. Geskin, M.D. (3) · Paul Martin (3) · Thomas E. Witzig, MD (3) · Youn H Kim, MD (3)
PMID 32632956, PMID 32499241, PMID 22045986, PMID 23069814, PMID 23770157, PMID 25795722, PMID 33072126, PMID 33883258, PMID 34091453, PMID 35175355, PMID 35536441, PMID 10552943, PMID 10764422, PMID 11231324, PMID 11410496, PMID 11675364, PMID 11895901, PMID 12525530, PMID 12543862, PMID 12588222, PMID 12873880, PMID 14630685, PMID 15107815, PMID 15459300, PMID 16135477, PMID 16148284, PMID 16710026, PMID 17020988, PMID 17119113, PMID 17397698, PMID 17515522, PMID 17854367, PMID 18327587, PMID 18463792, PMID 18645136, PMID 18698002, PMID 19170225, PMID 19199905, PMID 19451403, PMID 19789320, PMID 19826128, PMID 19841031, PMID 19900571, PMID 20142598, PMID 20166206, PMID 20229590, PMID 20697067, PMID 21135857, PMID 21247755, PMID 21355097
P30CA015704 (15), P30CA033572 (11), P30CA015083 (10), P30CA043703 (8), P30CA068485 (7), P30CA072720 (7), P30CA016672 (6), P01CA018029 (5), 2018 (4), P30CA016086 (4), P30CA022453 (4), P30CA060553 (4), U01CA062491 (4), U01CA062502 (4), U01CA076576 (4)